Promising COVID-19 Immunotherapy Targets CCR5
Clinical OMICs
America/Los_Angeles (PT) -7
Description
IncellDx specific companion diagnostic tests can determine the efficacy and dosing by using leronlimab (monoclonal antibody under flow cytometry) in severe cases of COVID-19 to determine the presence of CCR5. Evaluation of test results found that patients with severe COVID-19 disease are in the midst of immunologic chaos which includes the cytokine storm. IncellDx's companion diagnostics show that after three days of therapy, the immune profile in these patients approach normal levels and the levels of cytokines involved in the cytokine storm are much improved. Droplet Digital PCR (ddPCR) meets both testing needs for sensitivity and precision and has emerged as a go-to method for assessing the quality of patient-derived DNA samples from plasma. In this Clinical OMICs webinar, IncellDx presents an overview of CCR5 antagonists and the ddPCR data that enabled validation of their hypothesis to move 4 CCR5 inhibitors into trials for the treatment of COVID-19.
Promising COVID-19 Immunotherapy Targets CCR5
Inglês
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Speakers
Bruce Patterson
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.